Senores Pharmaceuticals Q2 Monitoring Report

Total IPO proceeds utilized stands at Rs 418.83 crore out of the Rs 500.00 crore raised.
Remaining unutilized balance is Rs 81.17 crore as of September 30, 2026.

Reader Takeaway: Company maintains transparent fund usage with no deviations, focusing now on active manufacturing facility expansion projects.

What just happened

CARE Ratings Limited has released its monitoring agency report for the quarter ended September 30, 2026, for Senores Pharmaceuticals. The report validates that the company has adhered to its stated objects for the Rs 500 crore IPO. There were zero unauthorized deviations reported.

Why this matters

For retail investors, the monitoring report serves as a governance check to ensure capital raised from the public is spent according to the promises made during the IPO process. With over 83% of the funds already deployed, the company is moving into the final stages of its capital expenditure cycle.

The backstory

Following a postal ballot on August 4, 2026, shareholders approved variations in the utilization of IPO funds. This allowed the company to adjust project timelines and object costs to better align with its current operational needs. These changes are reflected in the updated expenditure tracking provided by the monitoring agency.

Utilization of Proceeds

Significant capital has been directed toward inorganic growth and acquisitions, with the full allocation of Rs 161.91 crore already utilized. Ongoing projects include the Atlanta facility expansion and the Vadodara facility enhancement, which are currently progressing under the revised cost structures approved by shareholders.

Deployment of Unutilized Proceeds

The remaining Rs 81.17 crore is held securely in fixed deposits with ICICI Bank and a dedicated monitoring account with HDFC Bank. These funds are structured to reach maturity between October 2026 and January 2027, ensuring liquidity for the remaining project milestones.

What to track next

Investors should look for updates on the commissioning of the Atlanta sterile injection facility and the operational progress of the Vadodara expansion. These projects are now the primary drivers for the remaining capital deployment.